Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Clinical trial: treatment that improves colorectal cancer

Bevacizumab added to fluorouracil and leucovorin as first-line therapy for colorectal cancer, instead of irinotecan treatment, provides benefits including improvement in progression-free survival, reports June's Journal of Clinical Oncology.

News image

fiogf49gjkf04

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer.

The researchers had shown in a previous combined analysis of efficacy data from 3 studies the benefits of bevacizumab plus fluorouracil and leucovorin for metastatic colorectal cancer.

Dr Kabbinavar and colleagues undertook a randomized, phase II trial comparing bevacizumab plus fluorouracil and leucovorin versus placebo.

Survival was 17 months for combination with bevacizumab and 13 months for combination with placebo
Journal of Clinical Oncology

The research team also considered fluorouracil and leucovorin as first-line therapy in nonoptimal candidates for first-line irinotecan.

The team reported that patients had metastatic colorectal cancer and were 65 years of age.

The patients had an Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin of 4 g/dL, or prior abdominal/pelvic radiotherapy.

The researchers randomized 105 patients to fluorouracil,leucovorin and placebo and 104 to fluorouracil,leucovorin and bevacizumab.

The primary end point was survival, whilst secondary end points were progression-free survival, response rate, response duration, quality of life, and safety.

The team found that median survival was 17 months for the fluorouracil, leucovorin and bevacizumab group and 13 months for the fluorouracil, leucovorin and placebo group.

Median progression-free survival was 9 months with the fluorouracil, leucovorin and bevacizumab group.

The researchers noted that median progression-free survival was 6 months in the fluorouracil, leucovorin and placebo group.

The research team observed response rates of 26% in the fluorouracil, leucovorin and bevacizumab group and 15% with fluorouracil, leucovorin and placebo.

In addition, the team noted a response duration of 9 months with fluorouracil, leucovorin and bevacizumab and 7 months in fluorouracil, leucovorin and placebo.

The researchers found that hypertension was more common with bevacizumab but was controlled with oral medication, and did not cause drug discontinuation.

Dr Kabbinavar's team concludes, “Bevacizumab was added to fluorouracil and leucovorin as first-line therapy in patients with colorectal cancer who were not considered optimal candidates for first-line irinotecan treatment.”

“This provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.”

J Clin Oncol 2005: 23(16): 3697-705
03 June 2005

Go to top of page Email this page Email this page to a colleague

 23 May 2018 
High body mass index is and ulcerative colitis
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us